Patents Assigned to 180 Therapeutics LP
-
Publication number: 20230220060Abstract: The subject invention provides a method of treating an individual afflicted with early stage Dupuytren's disease characterized by the presence of one or more nodules on the individual's hand which comprises injecting into each nodule a pharmaceutical composition comprising an amount of an antihuman TNFa antibody or fragment thereof effective to treat the individual, wherein the pharmaceutical composition is in the form of a liquid and between 0.1 ml and 0.6 ml of the composition is injected into each nodule. This invention also provides for a pre-filled syringe for carrying out the above-described method.Type: ApplicationFiled: February 24, 2023Publication date: July 13, 2023Applicant: 180 Therapeutics LPInventors: Jagdeep Nanchahal, Glenn R. Larsen, Marc Feldmann
-
Patent number: 11613570Abstract: The subject invention provides a method of treating an individual afflicted with early stage Dupuytren's disease characterized by the presence of one or more nodules on the individual's hand which comprises injecting into each nodule a pharmaceutical composition comprising an amount of an antihuman TNFa antibody or fragment thereof effective to treat the individual, wherein the pharmaceutical composition is in the form of a liquid and between 0.1 ml and 0.6 ml of the composition is injected into each nodule. This invention also provides for a pre-filled syringe for carrying out the above-described method.Type: GrantFiled: April 14, 2022Date of Patent: March 28, 2023Assignee: 180 THERAPEUTICS LPInventors: Jagdeep Nanchahal, Glenn R. Larsen, Marc Feldmann
-
Patent number: 11400154Abstract: The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The subject invention also provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of a TNF receptor 2 (TNFR2) antagonist effective to treat the patient.Type: GrantFiled: December 9, 2019Date of Patent: August 2, 2022Assignee: 180 THERAPEUTICS LPInventors: Glenn Larsen, Jagdeep Nanchahal, Marc Feldmann
-
Publication number: 20220235125Abstract: The subject invention provides a method of treating an individual afflicted with early stage Dupuytren's disease characterized by the presence of one or more nodules on the individual's hand which comprises injecting into each nodule a pharmaceutical composition comprising an amount of an antihuman TNFa antibody or fragment thereof effective to treat the individual, wherein the pharmaceutical composition is in the form of a liquid and between 0.1 ml and 0.6 ml of the composition is injected into each nodule. This invention also provides for a pre-filled syringe for carrying out the above-described method.Type: ApplicationFiled: April 14, 2022Publication date: July 28, 2022Applicant: 180 Therapeutics LPInventors: Jagdeep Nanchahal, Glenn R. Larsen, Marc Feldmann
-
Publication number: 20210386855Abstract: The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The subject invention also provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of a TNF receptor 2 (TNFR2) antagonist effective to treat the patient. The invention additionally provides a method of treating a patient suffering from liver fibrosis of lung fibrosis which comprises administering to the patient an amount of a TNFR2 antagonist effective to treat the patient.Type: ApplicationFiled: July 29, 2021Publication date: December 16, 2021Applicant: 180 Therapeutics LPInventors: Glenn Larsen, Jagdeep Nanchahal, Marc Feldmann
-
Publication number: 20210040196Abstract: The subject invention provides a method of treating an individual afflicted with early stage Dupuytren's disease characterized by the presence of one or more nodules on the individual's hand which comprises injecting into each nodule a pharmaceutical composition comprising an amount of an antihuman TNFa antibody or fragment thereof effective to treat the individual, wherein the pharmaceutical composition is in the form of a liquid and between 0.1 ml and 0.6 ml of the composition is injected into each nodule. This invention also provides for a pre-filled syringe for carrying out the above-described method.Type: ApplicationFiled: April 6, 2017Publication date: February 11, 2021Applicant: 180 Therapeutics LPInventors: Jagdeep NANCHAHAL, Glenn R. LARSEN, Marc FELDMAN
-
Publication number: 20200338193Abstract: The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The subject invention also provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of a TNF receptor 2 (TNFR2) antagonist effective to treat the patient.Type: ApplicationFiled: December 9, 2019Publication date: October 29, 2020Applicant: 180 Therapeutics LPInventors: Glenn Larsen, Jagdeep Nanchahal, Marc Feldmann
-
Patent number: 10500273Abstract: The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The subject invention also provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of a TNF receptor 2 (TNFR2) antagonist effective to treat the patient.Type: GrantFiled: February 29, 2016Date of Patent: December 10, 2019Assignee: 180 Therapeutics LPInventors: Glenn Larsen, Jagdeep Nanchahal, Marc Feldmann
-
Publication number: 20190202907Abstract: The subject invention provides a method of treating a patient suffering from a systemic fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The invention also provides a method of treating a patient suffering from a systemic fibrotic condition which comprises administering to the patient an amount of a bispecific antibody comprising an IL-33 antigen binding domain of which (i) binds to and inhibits activation of, an IL-33 receptor, or (ii) specifically binds to IL-33 and inhibits IL-33 from binding to the IL-33 receptor, and a TNF antigen binding domain of which (i) binds to and inhibits activation of, a TNF receptor, or (ii) specifically binds to TNF and inhibits TNF from binding to the TNF receptor, wherein the bispecific antibody is effective to treat the patient.Type: ApplicationFiled: August 31, 2017Publication date: July 4, 2019Applicant: 180 Therapeutics LPInventors: Jagdeep Nanchahal, Glenn R. Larsen, Marc Feldmann
-
Publication number: 20180036404Abstract: The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The subject invention also provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of a TNF receptor 2 (TNFR2) antagonist effective to treat the patient. The invention additionally provides a method of treating a patient suffering from liver fibrosis of lung fibrosis which comprises administering to the patient an amount of a TNFR2 antagonist effective to treat the patient.Type: ApplicationFiled: February 29, 2016Publication date: February 8, 2018Applicant: 180 Therapeutics LPInventors: Glenn Larsen, Jagdeep Nanchahal, Marc Feldmann
-
Publication number: 20180030130Abstract: The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient. The subject invention also provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of a TNF receptor 2 (TNFR2) antagonist effective to treat the patient.Type: ApplicationFiled: February 29, 2016Publication date: February 1, 2018Applicant: 180 Therapeutics LPInventors: Glenn Larsen, Jagdeep Nanchahal, Marc Feldmann
-
Publication number: 20160158325Abstract: The subject invention also provides a method of treating a subject afflicted with a fibroproliferative disorder comprising periodically administering to the patient an amount of one or more human matrix metalloproteinase, wherein the one or more human matrix metalloproteinase are selected from human metalloproteinase-1 (MMP-1), human metalloproteinase-2 (MMP-2), human metalloproteinase-3 (MMP-3), human metalloproteinase-7 (MMP-7), human metalloproteinase-8 (MMP-8), human metalloproteinase-9 (MMP-9), human metalloproteinase-10 (MMP-10), human metalloproteinase-11 (MMP-11), metalloproteinase-12 (MMP-12), and human metalloproteinase-13 (MMP-13), and wherein the amount is effective to treat the subject. In an embodiment, the invention further comprises periodically administering to the subject an amount of TNF antagonist, wherein the amount of one or more the human matrix metalloproteinase and the amount of TNF antagonist when taken together are effective to treat the subject.Type: ApplicationFiled: July 9, 2014Publication date: June 9, 2016Applicant: 180 Therapeutics LPInventor: Glenn LARSEN